select a format

Single User License
USD 2000 INR 0
Site License
USD 4000 INR 0
Corporate User License
USD 6000 INR 0


Request a quote
Request a Customized research
Request for Sample Report


Recent Viewed Reports

Why Ken Reasearch?


The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

Eosinophilic Esophagitis-Pipeline Review, H2 2015

Eosinophilic Esophagitis-Pipeline Review, H2 2015

  • Products Id :- GMDHC6935IDB
  • |
  • Pages: 57
  • |
  • July 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Eosinophilic Esophagitis-Pipeline Review, H2 2015


Global Markets Direct's, 'Eosinophilic Esophagitis-Pipeline Review, H2 2015', provides an overview of the Eosinophilic Esophagitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Eosinophilic Esophagitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Eosinophilic Esophagitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Eosinophilic Esophagitis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Eosinophilic Esophagitis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Eosinophilic Esophagitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Eosinophilic Esophagitis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Eosinophilic Esophagitis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Eosinophilic Esophagitis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@]

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Eosinophilic Esophagitis Overview 6

Therapeutics Development 7

Pipeline Products for Eosinophilic Esophagitis-Overview 7

Eosinophilic Esophagitis-Therapeutics under Development by Companies 8

Eosinophilic Esophagitis-Pipeline Products Glance 9

Late Stage Products 9

Clinical Stage Products 10

Early Stage Products 11

Eosinophilic Esophagitis-Products under Development by Companies 12

Eosinophilic Esophagitis-Companies Involved in Therapeutics Development 13

Allergan Plc 13

DBV Technologies S.A. 14

Dr. Falk Pharma GmbH 15

Novartis AG 16

Receptos, Inc. 17

Regeneron Pharmaceuticals, Inc. 18

Shire Plc 19

Eosinophilic Esophagitis-Therapeutics Assessment 20

Assessment by Monotherapy Products 20

Assessment by Target 21

Assessment by Mechanism of Action 23

Assessment by Route of Administration 25

Assessment by Molecule Type 27

Drug Profiles 29

Allergen for Milk Allergy-Drug Profile 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

budesonide-Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

budesonide-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

dectrekumab-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

dupilumab-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

EUR-1100-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

Qi-406-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

RPC-4046-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

Eosinophilic Esophagitis-Recent Pipeline Updates 42

Eosinophilic Esophagitis-Dormant Projects 49

Eosinophilic Esophagitis-Product Development Milestones 50

Featured News & Press Releases 50

Oct 03, 2014: Receptos Announces First Patient Treated With Anti-Interleukin-13 Antibody in Phase 2 Trial for Eosinophilic Esophagitis 50

Sep 25, 2014: Meritage Pharma Announces Positive Results of Oral Budesonide Suspension for Treatment of Eosinophilic Esophagitis in Adolescent and Adult Patients 50

Jul 21, 2014: High-dose fluticasone effective against eosinophilic esophagitis 51

May 13, 2014: DBV Technologies Announces Clinical Trial Agreement to Develop a Treatment for Milk-Induced Eosinophilic Esophagitis in Children 52

Aug 13, 2012: Meritage Initiates Clinical Trial of Oral Budesonide Suspension for Adolescent and Adult Patients with Eosinophilic Esophagitis 52

May 10, 2011: Meritage Pharma Reports Positive Phase IIb Data for Oral Budesonide Suspension in Pediatric Patients with Eosinophilic Esophagitis 53

May 10, 2011: Meritage Reports Positive Phase IIb Data for Oral Budesonide Suspension in Pediatric Patients With Eosinophilic Esophagitis 54

Appendix 56

Methodology 56

Coverage 56

Secondary Research 56

Primary Research 56

Expert Panel Validation 56

Contact Us 56

Disclaimer 57

List of Tables

Number of Products under Development for Eosinophilic Esophagitis, H2 2015 7

Comparative Analysis by Late Stage Development, H2 2015 9

Comparative Analysis by Clinical Stage Development, H2 2015 10

Comparative Analysis by Early Stage Development, H2 2015 11

Products under Development by Companies, H2 2015 12

Eosinophilic Esophagitis-Pipeline by Allergan Plc, H2 2015 13

Eosinophilic Esophagitis-Pipeline by DBV Technologies S.A., H2 2015 14

Eosinophilic Esophagitis-Pipeline by Dr. Falk Pharma GmbH, H2 2015 15

Eosinophilic Esophagitis-Pipeline by Novartis AG, H2 2015 16

Eosinophilic Esophagitis-Pipeline by Receptos, Inc., H2 2015 17

Eosinophilic Esophagitis-Pipeline by Regeneron Pharmaceuticals, Inc., H2 2015 18

Eosinophilic Esophagitis-Pipeline by Shire Plc, H2 2015 19

Assessment by Monotherapy Products, H2 2015 20

Number of Products by Stage and Target, H2 2015 22

Number of Products by Stage and Mechanism of Action, H2 2015 24

Number of Products by Stage and Route of Administration, H2 2015 26

Number of Products by Stage and Molecule Type, H2 2015 28

Eosinophilic Esophagitis Therapeutics-Recent Pipeline Updates, H2 2015 42

List of Figures

Number of Products under Development for Eosinophilic Esophagitis, H2 2015 7

Number of Products under Development by Companies, H2 2015 8

Comparative Analysis by Clinical Stage Development, H2 2015 10

Assessment by Monotherapy Products, H2 2015 20

Number of Products by Targets, H2 2015 21

Number of Products by Stage and Targets, H2 2015 21

Number of Products by Mechanism of Actions, H2 2015 23

Number of Products by Stage and Mechanism of Actions, H2 2015 23

Number of Products by Routes of Administration, H2 2015 25

Number of Products by Stage and Routes of Administration, H2 2015 25

Number of Products by Molecule Types, H2 2015 27

Number of Products by Stage and Molecule Types, H2 2015 27

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@]

Allergan Plc

DBV Technologies S.A.

Dr. Falk Pharma GmbH

Novartis AG

Receptos, Inc.

Regeneron Pharmaceuticals, Inc.

Shire Plc

Eosinophilic Esophagitis Therapeutic Products under Development, Key Players in Eosinophilic Esophagitis Therapeutics, Eosinophilic Esophagitis Pipeline Overview, Eosinophilic Esophagitis Pipeline, Eosinophilic Esophagitis Pipeline Assessment

Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

query [@]